Related Experiment Video
Updated: Apr 8, 2026

07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
24.2K
Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?
Dario Cocito1, Aristide Merola1, Alberto Romagnolo1
1Department of Neuroscience, University of Turin, Torino, Italy.
Journal of Neurology, Neurosurgery, and Psychiatry
|June 26, 2015
Abstract
No abstract available in PubMed .
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
776
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
776
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
704
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
704

